Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957766 | 0.97 | RIPK1 (0.55) | RIPK1MCL1ALDH1A1PKMSLC6A4 | |
| SCHEMBL22957805 | 0.95 | RIPK1 (0.54) | RIPK1MCL1ALDH1A1PKMSLC6A4 | |
| SCHEMBL22957615 | 0.94 | RIPK1 (0.62) | RIPK1MCL1ALDH1A1PKMSLC6A4 | |
| SCHEMBL22957816 | 0.85 | RIPK1 (0.60) | RIPK1PKMSLC6A4HTR2CSLC6A2 | |
| SCHEMBL22957672 | 0.82 | RIPK1 (0.60) | RIPK1PKMSLC6A4HTR2CSLC6A2 | |
| SCHEMBL24018785 | 0.81 | RIPK1 (0.51) | RIPK1ALDH1A1SLC6A4HTR2CSLC6A2 | |
| SCHEMBL22957645 | 0.81 | SLC6A4 (0.49) | ALDH1A1PKMSLC6A4HTR2AHTR2C | |
| SCHEMBL22957804 | 0.81 | RIPK1 (0.51) | RIPK1POLBMCHR1 | |
| SCHEMBL22957616 | 0.80 | RIPK1 (0.57) | RIPK1ALDH1A1SLC6A4HTR2CSLC6A2 | |
| SCHEMBL22957811 | 0.80 | HTR2A (0.55) | SLC6A4HTR2AHTR2CSLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3580220-B1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | RIPK1 1/4885MCL1 1442/4885ALDH1A1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.